Abstract:Background: Yes-associated protein 1 (YAP1) is the main downstream effector of the Hippo signaling pathway, which is involved in tumorigenesis. This study aimed to comprehensively understand the prognostic performances of YAP1 expression and its potential mechanism in pan-cancers by mining databases. Methods: The YAP1 expression was evaluated by the Oncomine database and GEPIA tool. The clinical significance of YAP1 expression was analyzed by the UALCAN, GEPIA, and DriverDBv3 database. Then, the co-expressed genes with YAP1 were screened by the LinkedOmics, and annotated by the Metascape and DAVID database. Additionally, by the MitoMiner 4.0 v tool, the YAP1 co-expressed genes were screened to obtain the YAP1-associated mitochondrial genes that were further enriched by DAVID and analyzed by MCODE for the hub genes. Results: YAP1 was differentially expressed in human cancers. Higher YAP1 expression was significantly associated with poorer overall survival and disease-free survival in adrenocortical carcinoma (ACC), brain Lower Grade Glioma (LGG), and pancreatic adenocarcinoma (PAAD). The LinkedOmics analysis revealed 923 co-expressed genes with YAP1 in adrenocortical carcinoma, LGG and PAAD. The 923 genes mainly participated in mitochondrial functions including mitochondrial gene expression and mitochondrial respiratory chain complex I assembly. Of the 923 genes, 112 mitochondrial genes were identified by MitoMiner 4.0 v and significantly enriched in oxidative phosphorylation. The MCODE analysis identified three hub genes including CHCHD1, IDH3G and NDUFAF5. Conclusion: Our findings showed that the YAP1 overexpression could be a biomarker for poor prognosis in ACC, LGG and PAAD. Specifically, the YAP1 co-expression genes were mainly involved in the regulation of mitochondrial function especially in oxidative phosphorylation. Thus, our findings provided evidence of the carcinogenesis of YAP1 in human cancers and new insights into the mechanisms underlying the role of YAP1 in mitochondrial dysregulation.

Transforming Properties of Yap, A Candidate Oncogene on the Chromosome 11q22 Amplicon

Inactivation of Yap Oncoprotein by the Hippo Pathway is Involved in Cell Contact Inhibition and Tissue Growth Control

TEAD Mediates YAP-dependent Gene Induction and Growth Control

Both Tead-Binding and Ww Domains Are Required for the Growth Stimulation and Oncogenic Transformation Activity of Yes-Associated Protein

Abstract A12: YAP‐dependent induction of amphiregulin identifies a non‐cell‐autonomous component of the Hippo pathway

YAP/TAZ for Cancer Therapy: Opportunities and Challenges (Review).

YAP/TAZ for cancer therapy: Opportunities and challenges (Review)

GENE-04. THE ONCOGENIC FUNCTIONS OF YAP1-GENE FUSIONS CAN BE INHIBITED BY DISRUPTION OF YAP1-TEAD INTERACTION

Oncogenic YAP mediates changes in chromatin accessibility and activity that drive cell cycle gene expression and cell migration

Abstract LB-228: YAP-dependent Induction of Amphiregulin Identifies a Non-Cell-autonomous Component of the Hippo Pathway

The Hippo-YAP pathway: new connections between regulation of organ size and cancer.

Negative Regulation Of Yap By Lats1 Underscores Evolutionary Conservation Of The Drosophila Hippo Pathway

Quantitative Real-Time PCR to Measure YAP/TAZ Activity in Human Cells.

The Dual Functions of YAP-1 to Promote and Inhibit Cell Growth in Human Malignancy.

Data from Negative Regulation of YAP by LATS1 Underscores Evolutionary Conservation of the <i>Drosophila Hippo</i> Pathway

SET1A-Mediated Mono-Methylation at K342 Regulates YAP Activation by Blocking Its Nuclear Export and Promotes Tumorigenesis.

The Hippo-YAP Pathway in Organ Size Control and Tumorigenesis: an Updated Version.

The Hippo Signaling Pathway Coordinately Regulates Cell Proliferation and Apoptosis by Inactivating Yorkie, the Drosophila Homolog of YAP

YAP Overexpression in Breast Cancer Cells Promotes Angiogenesis Through Activating YAP Signaling in Vascular Endothelial Cells

Gene Regulation Network of Prognostic Biomarker YAP1 in Human Cancers: An Integrated Bioinformatics Study

YAP1 is a key regulator of EWS::FLI1-dependent malignant transformation upon IGF-1 mediated reprogramming of bone mesenchymal stem cells